The Fred Hutchinson/University of Washington Cancer Consortium (Consortium), formed in 2002, is a partnership of: Fred Hutchinson Cancer Research Center, an NCI-designated Comprehensive Cancer Center since 1976 and a CCSG grant recipient since 1973;the University of Washington;and Children's Hospital and Regional Medical Center. The Consortium brings together more than 400 faculty with research interests in basic, clinical and public health sciences related to cancer, with total NCI funding of $73 million (direct costs). The goal of the Consortium is the elimination of cancer through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration between the three institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. The Consortium faculty are organized into 13 productive research programs with emphasis in the Public Health (Biostatistics, Epidemiology, Cancer Prevention), Clinical (Transplantation Biology and Clinical Transplantation), and Fundamental sciences (Basic Sciences, Stem/Progenitor Cell Biology, Genome Instability &Mutagenesis), as well as programs that are highly cross-disciplinary (Women's Cancer;Prostate Cancer;Gl Cancer Etiology, Prevention, &Early Detection;Cancer Imaging;and Immunology &Vaccine Development). During the next grant period the Consortium will seek to: (1) Strengthen its clinical research programs and infrastructure to permit more rapid development of diagnostics and therapeutics;(2) Strengthen its presence in genetic/genomics;(3) Strengthen its presence in computational biology;(4) Continue its commitment to early cancer detection, including protein biomarker discovery and molecular diagnostics;(5) Build on leadership in research on infectious diseases and virology and develop a program focusing on infectious agents and cancer;(6) Continue to recruit promising laboratory scientists in broad areas of basic biology;and (7) Continue to encourage and support a focus on aging for relevant programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-39
Application #
8412707
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-01-01
Project End
2013-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
39
Fiscal Year
2013
Total Cost
$10,072,717
Indirect Cost
$3,842,203
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Witzky, Anne; Hummels, Katherine R; Tollerson 2nd, Rodney et al. (2018) EF-P Posttranslational Modification Has Variable Impact on Polyproline Translation in Bacillus subtilis. MBio 9:
Rosenthal, Elisabeth A; Shirts, Brian H; Amendola, Laura M et al. (2018) Rare loss of function variants in candidate genes and risk of colorectal cancer. Hum Genet 137:795-806
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Correction: Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis (doi:10.1242/211573). J Cell Sci 131:

Showing the most recent 10 out of 1267 publications